Download the ETPharma App and get the Realtime updates and Save your favourite articles. London: Britain's GSK has ⁠agreed to buy RAPT Therapeutics for $2.2 billion, accessing the U.S. biotech's experimental drug to treat food allergies as it seeks new medicines ahead of patent losses for a top-selling HIV drug.The deal comes weeks after new CEO Luke Miels took over from Emma Walmsley. In December, the company won U.S. approval for a twice-yearly asthma drug. 'VALIDATED TARGETS'The RAPT deal gives GSK global rights to ozureprubart outside mainland China, Macau, Taiwan and Hong Kong. Novartis, Genentech's partner on Xolair, is also testing another drug, remibrutinib, for food allergy.

Source: Economic Times January 21, 2026 03:29 UTC